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Abstract
A novel swine-origin pandemic influenza A(H1N1) virus (H1N1pdm, also referred to as S-OIV) was identified as the causative
agent of the 21
st century’s first influenza pandemic, but molecular features conferring its ability of human-to-human
transmission has not been identified. Here we compared the protein sequences of 2009 H1N1pdm strains with those
causing other pandemics and the viruses isolated from humans, swines and avians, and then analyzed the mutation trend of
the residues at the signature and non-signature positions, which are species- and non-species-associated, respectively, in
the proteins of H1N1pdm during the pandemic of 2009. We confirmed that the host-specific genomic signatures of 2009
H1N1pdm, which are mainly swine-like, were highly identical to those of the 1918 H1N1pdm. During the short period of
time when the pandemic alert level was raised from phase 4 to phase 6, one signature residue at the position of NP-100
mutated from valine to isoleucine. Four non-signature residues, at positions NA-91, NA-233, HA-206, and NS1-123, also
changed during the epidemic in 2009. All these mutant residues, except that at NA-91, are located in the viral functional
domains, suggesting that they may play roles in the human adaption and virulence of 2009 H1N1pdm.
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Introduction
In April 2009, a new influenza A(H1N1) was reported in
Mexico and the southwestern United States [1]. The World
Health Organization (WHO) boosted its pandemic alert levels for
this flu to phase 4 on 27 April 2009, phase 5 on 29 April 2009, and
phase 6 on 11 June 2009, declaring a full-blown influenza
pandemic for the first time in 41 years. As of 24 January 2010, the
laboratory-confirmed cases of pandemic influenza H1N1 2009,
including at least 14,711 deaths, had been reported in more than
209 countries and overseas territories or communities worldwide
(http://www.who.int/csr/don/2010_01_29/en/index. html).
The causative agent was proven to be a novel swine-origin
pandemic influenza A (H1N1) virus (H1N1pdm, also referred to as
S-OIV). Its hemagglutinin (HA), nucleoprotein (NP), and nonstruc-
tural (NS) protein genes belong to the classical swine lineage, while
its neuraminidase (NA) and matrix (M) protein genes derive from a
Eurasian swine influenza lineage which entered pigs from avian
hosts around 1979, and its polymerase gene segments, PA, PB1 and
PB2, descended from the North American triple reassortant swine
lineage [2–5]. This unique genetic combination may contribute to
the improved fitness of the H1N1pdm in humans and its human-to-
human transmissibility, although none of the molecular features
previously shown to confer increased human-to-human transmis-
sibility has so far been identified in the 2009 H1N1pdm. Since there
is a serious concern that the virus may further mutate into a more
dangerous form (http://www.cbsnews.com/stories/2009/12/29/
health/main6034632.shtml), it is critical to monitor the evolution-
ary trends of the 2009 H1N1pdm virus.
Shih and colleagues previously developed an entropy-based
computational scheme to identify host-specific genomic signatures
of human and avian influenza viruses [6]. Most recently, they used
this method to compare the protein sequences of the 2009
H1N1pdm strains collected before May 28, 2009, with those of
avian, swine and human influenza A viruses (IAVs). Among the 47
avian-human signatures, they found that 8 (one in PB1, one in
PB2, 2 in PA and 4 in NP) showed human-characteristic
signatures, which may serve as a molecular marker for monitoring
adaptive mutations in the influenza viruses [7].
In the present study, we compared the protein sequences of
2009 H1N1pdm strains collected from April 1, 2009 to December
31, 2009, with the corresponding protein sequences of the human,
avian, and swine IAVs and those causing past influenza
pandemics. We then conducted an analysis to gain insight into
1) the mutation trend of the residues at the signature and non-
signature positions in the proteins of H1N1pdm during the
pandemic of 2009 and 2) the potential roles of the mutated
residues in human adaptation and virulence of the 2009
H1N1pdm influenza virus.
Results and Discussion
Comparison of Genomic Signatures of 2009 H1N1pdm
with Human, Swine and Avian Influenza A Viruses, as Well
as Those of Other Pandemic Influenza Viruses
The consensus protein sequences of the 2009 H1N1pdm were
aligned with those of human, avian and swine IAVs collected
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9549Table 1. Comparison of the amino acid signatures in the proteins of 2009 H1N1pdm with those in human, swine, and avian IAVs,
as well as those causing past influenza pandemics.
Protein Position Amino acid signatures
2009 H1N1 1918 H1N1 1957H2N2 1968 H3N2 1977 H1N1 Human Swine Avian
PB2 44 A A S S S S A A
199 A A S S S S A A
2 7 1 ATAAAA AT
475 L L M M M M L L
5 6 7 DNNNNI DD
5 8 8T A IIII T A
613 V V T T T T V V
6 2 7 EKKKKK EE
7 0 2 KRRRRR KE
PB1 327 R R R K R K R R
336 I V V V I I I V
PA 28 P L L L L L P P
5 5 DNNNNN DD
5 7 RRQQQQ RR
1 0 0 VAAAAA VV
225 S S C C C C S S
268 L L I I I I L L
3 5 6 RKRRRR KK
404 A A S S S S A A
4 0 9 NSNNNN NS
5 5 2 TSSSSS TT
NP 16 G D D D D D G G
3 3 IIIIII IV
6 1 I I LLLL I I
1 0 0 VI VVVV VR
1 0 9 I I VVVV I I
2 1 4 RRKKKK RR
2 8 3 LPPPPP LL
2 9 3 RRKKKK RR
3 0 5 KRKKKK KR
3 1 3 VYYYYY FF
3 5 7 KKKKKK KQ
372 E E D D D D E E
4 2 2 RRKKKK RR
4 4 2 TTAAAA TT
455 D D E E E E D D
M1 115 V V I I I I V V
1 2 1 TAAAAA TT
1 3 7 TAAAAA TT
M2 11 T T I I I I T T
2 0 SNNNNN SS
5 7 YYHHHH YY
8 6 VVAAAA VV
93 N N S S N S N N
NS1 81 I I M M M M I I
227 delete K R R R R G E
NS2 107 L L F F F F L L
Note: Only the dominant residues were listed. The human-like amino acid signatures in the 2009 H1N1pdm were highlighted in bold and italic.
doi:10.1371/journal.pone.0009549.t001
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The residues in the protein sequences of each group located at the
avian-human signature positions described by Chen et al. [7] were
listed in Table 1. The signature residues in the proteins of the 2009
H1N1pdm strains collected in the pre-epidemic period were 17%,
94% and 75% identical to those of human, swine and avian IAVs,
respectively (Table 2), confirming that the 2009 H1N1pdm
originated from swine influenza virus. Notably, the 2009
H1N1pdm exhibited 55%, 15%, 13% and 19% identity of the
signatures to the 1918 H1N1pdm, 1957 H2N2pdm, 1968
H3N2pdm and 1977 H1N1pdm, respectively. Similarly, the
1918 H1N1pdm exhibited low similarity of the signatures to
human IAVs, while those causing the 1957 H2N2, 1968 H3N2
and 1977 H1N1 pandemics displayed high (.94%) identity of the
signatures to human IAVs (Table 2). While these pandemic viruses
can all be efficiently transmitted in humans, these results suggest
that the 2009 H1N1pdm and 1918 H1N1pdm have much lower
human-like signatures than other pandemic influenza viruses,
including the 1977 H1N1pdm. Like the 1918 H1N1pdm that had
a sister relationship with the ‘‘classic’’ swine H1N1 lineage [8], the
2009 H1N1pdm had closer linkage to swine IAVs than avian and
human IAVs. Therefore, it is worthwhile to identify the signature
or non-signature residues shared by the 2009 H1N1pdm and 1918
H1N1pdm that may play roles in viral transmission and virulence.
Unlike seasonal flu that usually hits elderly people the hardest,
the 2009 H1N1pdm has mostly infected the young, especially
school-aged children [9]. Persons born before 1957 had a reduced
risk of 2009 H1N1pdm infection [10], suggesting that the
immunity induced by the viruses causing influenza pandemics
after 1957 are ineffective in protecting people from infection by
the 2009 H1N1pdm. After assessing human sera from different
age groups, Itoh et al. [3] found that elderly people exposed to the
1918 H1N1pdm had antibodies that cross-neutralized the 2009
H1N1pdm. Hancock et al. [11] also reported that persons under
the age of 30 years had little evidence of cross-reactive antibodies
to the 2009 H1N1pdm virus, while people born before 1930, who
were probably exposed to a 1918 H1N1pdm-like virus, had the
highest titers of antibodies against the 2009 H1N1pdm. These
findings suggest that the 2009 and 1918 H1N1pdm viruses have
high antigenic and immunogenic similarities, raising serious
concerns that the 2009 H1N1pdm may follow an evolutionary
path similar to that of the 1918 H1N1pdm.
Mutation Trend Analysis of the Signature and Non-
Signature Residues in Proteins of 2009 H1N1pdm Isolates
Collected at the Different Periods in the 2009 Pandemic
We compared the signature and non-signature residues of the
proteins in the 2009 H1N1pdm strains collected at the pre-
epidemic, early, middle and late periods of the pandemic in 2009.
We found that among the 47 avian-human signatures [7], only one
signature residue at position 100 of NP exhibited a dominant
change during the 2009 epidemic. In the pre-epidemic period,
only 10% of 2009 H1N1pdm strains had valine to isoleucine
change at position NP-100, whereas about 57%, 80% and 93% of
the virus isolates collected in the early, middle and late periods
possessed this change, respectively (Table 3 and Fig. 1), suggesting
that this V100I mutation may play some role in the increased
Table 2. The identity of amino acid signatures in the proteins of pandemic IAVs and human, swine, and avian IAVs.
Influenza A virus Identity (%) of amino acid signatures
2009 H1N1 1918 H1N1 1957 H2N2 1968 H3N2 1977 H1N1 Human Swine Avian
2009 H1N1pdm 47/47 (100) 26/47 (55) 7/47 (15) 6/47 (13) 9/47 (19) 8/47 (17) 44/47 (94) 35/47 (75)
1918 H1N1pdm - 47/47 (100) 17/47 (36) 16/47 (34) 18/47 (38) 14/47 (30) 26/47 (55) 30/47 (47)
1957 H2N2pdm - - 47/47 (100) 46/47 (98) 45/47 (96) 44/47 (94) 7/47 (15) 2/47 (4)
1968 H3N2pdm - - - 47/47 (100) 45/47 (96) 44/47 (94) 6/47 (13) 1/47 (2)
1977 H1N1pdm - - - - 47/47 (100) 45/47 (96) 9/47 (19) 1/47 (2)
doi:10.1371/journal.pone.0009549.t002
Table 3. Mutation trend analysis of signature and non-signature amino acid residues in the functional domains of the proteins of
2009 H1N1pdm during the influenza pandemic in 2009.
Viral Amino 2009 H1N1pdm strains collected during Dominant residues in proteins of IAV of
protein Acid Change
4/1/09–4/
15/09
4/16/09–5/
15/09
5/16/09–6/
15/09
6/16/09–12/
31/09 1918 1957 1968 1977 Human Swine Avian
residue
position
pre-epidemic
period early period middle period late period H1N1 H2N2 H3N2 H1N1
NP 100 VRI 3/29 (10) 231/403 (57) 249/313 (80) 236/254 (93) I V V V V V R
NA(N1) 91 VRI 4/38 (11) 281/494 (57) 314/383 (82) 486/566 (86) I - - I I I V
NA(N1) 233 NRD 4/38 (11) 300/584 (51) 303/398 (76) 505/589 (86) N - - D N N N
HA(H1) 206 SRT 0/43 (0) 139/524 (27) 183/416 (44) 500/601 (83) S - - S S S S
NS1 123 IRV 0/24 (0) 105/358 (29) 132/330 (40) 199/256 (78) I I I I I I I
Note: the number in brackets indicates the percent (%) of sequences with the mutated amino acid in total number of the sequences collected in the period; ‘-’ means
unavailable in non-H1N1 virus.
doi:10.1371/journal.pone.0009549.t003
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1918 H1N1pdm also had residue isoleucine at the position NP-
100, while other pandemic viruses and human IAVs display valine
(Table 3).
The influenza viral NP, which forms trimer as a part of the
helical genomic ribonucleoprotein complexes, plays a critical role
in viral RNA replication [12]. NP may also play a role in cross-
species transmission since among the ten IAV proteins, NP
contained the largest number (15 of 47) for genomic signatures
(Table 1). Each NP monomer, which contains 17 a-helices and 9
b-strands [13], consists of a head domain and a body domain
(Fig. 2A). The body domain is comprised of three segments (aa 21–
149, 273–396 and 453–489) responsible for binding to the PB1
and PB2 subunits of the viral polymerase [14]. The conserved
amino acid regions on the surface of the NP body domain that
mediate NP-polymerase interactions are crucial for viral RNA
replication. For example, an asparagine to lysine mutation at the
position 319, which is located on the surface of the body domain,
resulted in an increase of polymerase activity and adaptation of an
avian influenza virus to a mammalian host [15]. The residue at
NP-100, which is located in the body domain (Fig. 2A–C), is
thought to be involved in NP-PB2 interaction [14]. Given that the
majority of the viruses gained the V100I mutation during a short
period of time when the pandemic alert level was raised from
phase 4 to phase 6 (Table 3), this mutation may play a role in the
increased transmissibility or infection of the 2009 H1N1pdm.
Furthermore, we identified four dominant mutations of non-
signature residues in NA, HA, and NS1 proteins of the 2009
H1N1pdm virus. In NA protein, the avian-like residue, valine at
NA-91 mutated to the human-like residue isoleucine, which was
presented in the 1918 and 1977 H1N1pdm IAVs. The non-
charged residue, asparagine at NA-233, mutated to a negatively
charged residue, aspartic acid, which is only presented in the 1977
H1N1pdm IAVs. In the pre-epidemic period, about 11% of the
2009 H1N1pdm strains had the V91I mutation and/or N233D
mutation. In the early, middle, and late periods, 57%, 82%, and
86% of the viruses possessed V91I mutation, while 51%, 76% and
86% of the viral isolates had the N233D mutation, respectively
(Table 3 and Fig. 1), suggesting that many of the 2009 H1N1pdm
strains carried both NA V91I and NA N233D mutations.
In the process of virus infection, NA functions as a tetramer
(Fig. 2D) to remove sialic acid from cell-surface receptors to allow
the newly made virions to release and spread to uninfected cells
[16]. Therefore, NA serves as an important target for development
of anti-influenza drugs, such as oseltamivir (Tamiflu) [17] and
zanamivir (Relenza) [18]. A single-point mutation of the residues
located in the drug target domain (DTD), such as H260Y
mutation (corresponding to H274Y mutation in H5N1 viruses),
may result in viral resistance to oseltamivir [19]. Most recently, a
number of reports indicated that several clinically isolated 2009
H1N1pdm strains with NA H260Y mutation were resistant to the
NA inhibitor oseltamivir [20,21]. However, we did not find the
increased H260Y mutation in the 2009 H1N1pdm NA sequences
that we analyzed. Instead, we identified V91I and N233D
mutations in the majority of 2009 H1N1pdm isolates collected
at the late period of the 2009 epidemic. Since the residue at the
NA-233 position is also located in the DTD region (Fig. 2E) and
has close proximity to H260, it is worthwhile to investigate the
potential effect of N233D mutation on the sensitivity of the virus to
NA inhibitors. Since the amino acid at NA-91 is not located in the
DTD, the NA V91I mutation may have no direct effect on drug
sensitivity of the virus.
We identified one dominant mutation in HA, S206T with the
mutation rates of 0%, 27%, 44% and 83% in the 2009 H1N1pdm
Figure 1. The dominant mutations of the amino acid residues in NP, NA, HA, and NS1 in 2009 H1N1pdm isolates collected from
April 1, 2009 to October 25, 2009.
doi:10.1371/journal.pone.0009549.g001
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periods, respectively (Table 3 and Fig. 1). This is a unique
mutation because it was neither found in 1918 and 1977
H1N1pdm viruses, nor was it found in the human, swine and
avian IAVs. Interestingly, however, we found that the S206T
mutation transiently appeared in the HA sequences of human
H1N1 viruses collected in 1934 and in swine H1N1 viruses
collected in 1976 and 1977. S206 is located in the receptor-
binding domain (RBD) of HA (Fig. 2G-I)[22]. The binding of IAV
to erythrocytes and host cells is mediated by the interaction of its
HA RBD with the cell surface receptor containing sialic acid. The
RBD sequence is thus the major determinant of IAV host
specificity [23]; therefore, HA-206 SRT mutation may directly
affect the infectivity and transmissibility of 2009 H1N1pdm in
humans.
Another unique dominant mutation occurred in the NS1
protein, NS1-123 IRV, during the pandemic in 2009. None of the
IAVs collected in the pre-epidemic period carried this mutation,
Figure 2. Schematic representation of the functional domains with mutated residues in the 2009 H1N1pdm proteins. Left panels:
bird’s eye view of protein structures of 2009 H1N1pdm collected at the pre-epidemic period in 2009; Middle panels: close-up view of the mutated
amino acid residues in proteins of 2009 H1N1pdm collected at the pre-epidemic period in 2009; Right panels: close-up view of the mutated amino
acid residues in proteins of 2009 H1N1pdm collected at the late period in 2009. The amino acid numberings were based on influenza virus A/Puerto
Rico/8/1934 (H1N1) [6]. The residues in viruses collected in the pre-epidemic period are colored in red, and those in viruses collected in the late period
are colored in yellow. A–C: NP trimer and monomer. D–F: NA tetramer and monomer. Drug target domain (DTD) is highlighted in dark blue. H260
[274 in A/Vietnam/1203/04(H5N1)] is a critical residue for the NA inhibitor, oseltamivir. NA H274Y mutation results in resistance of 2009 H1N1pdm
and other influenza viruses to oseltamivir. G–I: HA trimer and monomer. Receptor binding domain (RBD) was highlighted in wheat color, while other
part is in green color. J–L: Dimer and monomer of effector domain (ED) in NS1.
doi:10.1371/journal.pone.0009549.g002
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in the early, middle and late periods possessed the NS1-123 IRV
mutation, respectively (Table 3 and Fig. 1). This dominant
mutation has not been observed in other IAVs that caused past
influenza pandemics. NS1, a 26-kDa protein, functions as a dimer
(Fig. 2J). Its monomer consists of seven b-strands and three a-
helices, which form the two functional domains, the RNA-binding
groove (RBG) and the effector domain (ED) (Fig. 2K) [24]. NS1 is
responsible for suppressing antiviral interferon (IFN) induction
during viral replication by preventing activation of the latent
transcription factors IRF-3 [25] and NF-kB [26]. The lethal
H5N1 strains with a point mutation, D92E, or a deletion of
residues 80-84 in the NS1 protein, exhibited increased virulence,
cytokine resistance or both [27]. The highly effective 1918
H1N1pdm NS1 protein as an inhibitor of type I IFN production
might have contributed to its exceptional virulence [25]. In the
2009 H1N1pdm virus, we did not find D92E or other mutations
that confer the high virulence of H5N1 and 1918 H1N1pdm
strains. Similarly, none of the previously identified virulence
factors, such as PB2-627 ERK mutation [28,29], has been
identified in the 2009 H1N1pdm. Consequently, the potential role
of the NS1-123 IRV mutation, which is located in the ED of NS1,
in virulence and host adaptation needs to be clarified.
In summary, our study confirms that the 2009 H1N1pdm virus
has much closer linkage to the 1918 H1N1pdm than any other
pandemic influenza viruses. We identified one dominant mutation
at the signature position (NP-100) and four dominant mutations at
the non-signature positions (NA-91, NA-233, HA-206, and NS1-
123). Except NA-91, all these mutant residues are located in the
viral functional domains, suggesting that they may play roles in the
human adaption and virulence of 2009 H1N1pdm.
Methods
Collection and Analysis of Influenza A Virus Sequences
To compare the protein sequences of the 2009 H1N1pdm with
those of other IAVs, we downloaded from the NCBI Influenza
Database the full-length or partial protein sequences of the IAVs
isolated between 2000 and 2008 from humans (H1N1 and H3N2),
avians (H1N1, H3N2, H5N1, and H9N2), and swines (H1N1,
H1N2, H2N3, H3N1, H3N2, H3N8, and H4N6, H5N1, and
H9N2),), and those causing past and current influenza pandemics,
including the 1918 H1N1pdm, 1957 H2N2pdm, 1968 H3N2pdm,
1977 H1N1pdm, and 2009 H1N1pdm. The 2009 H1N1pdm
strains were collected from April 1, 2009 to December 31, 2009
(according to NCBI records). The sequences of ten proteins,
including PB2, PB1, PA, HA(H1), NA(N1), NP, M1, M2, NS1,
and NS2, were analyzed. To monitor the mutation trend of the
2009 H1N1pdm, its protein sequences were divided into 4 groups
based on the time the sequences were collected: i) 4/1/09-4/15/
09 (pre-epidemic period); ii) 4/16/09-5/15/09 (early epidemic
period) when WHO raised the pandemic alert level from 4 to 5; iii)
5/16/09-6/15/09 (middle epidemic period) when WHO raised
the pandemic to level 6; and iv) 6/15/09-10/25/09 (late epidemic
period). Multiple sequence alignments were performed using an
online program (see http://www.ncbi.nlm.nih.gov/genomes/
FLU/FLU.html) to obtain the consensus sequences and to identify
the dominant mutations in each protein as previously described
[30]. A dominant mutation is defined here as one mutated residue
containing the largest sequence count compared with other
residues at a particular aligned position. All amino acid
numberings are based on influenza virus A/Puerto Rico/8/1934
(H1N1) [6].
Protein Modeling Analysis
Homology-based structural models of the functional domains
with or without mutations were constructed with templates
downloaded from the Protein Data Bank, including NP (PDB
ID: 2IQH), NA (PDB ID: 2HTY), HA (PDB ID: 1RUZ), and NS1
(PDB ID: 3F5T). Briefly, the model of the corresponding protein
(e.g., NP) was downloaded from Protein Data Bank and opened
with the PYMOL program. The residues in the protein model
were replaced with those at the corresponding positions in the
protein to be analyzed using the ‘‘Mutagenesis’’ function of
PYMOL program [31] (http://www.pymol.org). The main
functional domains in the protein were displayed and analyzed.
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